Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Verastem (VSTM – Research Report) today and set a price target of $9.00.

In a report released today, Gregory Renza from RBC Capital reiterated a Buy rating on Verastem (VSTM – Research Report), with a price target of ...

TAK-861 is under clinical development by Takeda Pharmaceutical and currently in Phase I for Unspecified Neurologic Disorders.

TAK-861 is under development for the treatment of narcolepsy (type 1) and unspecified neurological disorders. It is administered through oral route. The drug candidate acts by targeting orexin ...

According to latest analysis by Report Ocean, the global antibody drugs market is poised to grow by USD 91 billion during 2022-2028, progressing at a CAGR of 9.7% during the forecast period. Request ...

16."When I was in med school, there was a guy in his early 60s, fairly healthy, who kept coming into the hospital with vague ...

"We had a patient who came in insisting that her neighbor was poisoning her. Everyone dismissed her." View Entire Post › ...

Lymphoma is a type of cancer that begins in immune system cells, called lymphocytes. It generally presents as a solid tumor of lymphoid cells and can develop in the lymph nodes, spleen, bone ...

Use of immunomodulatory treatment for non-infectious uveitis: an International Ocular Inflammation Society report of real-world practice ...